Cargando…

The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses

An epidemiological model for COVID-19 was developed and implemented in MATLAB/GNU Octave for use by public health practitioners, policy makers, and the general public. The model distinguishes four stages in the disease: infected, sick, seriously sick, and better. The model was preliminarily paramete...

Descripción completa

Detalles Bibliográficos
Autor principal: De Visscher, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Netherlands 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416305/
https://www.ncbi.nlm.nih.gov/pubmed/32836820
http://dx.doi.org/10.1007/s11071-020-05861-7
_version_ 1783569302179282944
author De Visscher, Alex
author_facet De Visscher, Alex
author_sort De Visscher, Alex
collection PubMed
description An epidemiological model for COVID-19 was developed and implemented in MATLAB/GNU Octave for use by public health practitioners, policy makers, and the general public. The model distinguishes four stages in the disease: infected, sick, seriously sick, and better. The model was preliminarily parameterized based on observations of the spread of the disease. The model assumes a case mortality rate of 1.5%. Preliminary simulations with the model indicate that concepts such as “herd immunity” and containment (“flattening the curve”) are highly misleading in the context of this virus. Public policies based on these concepts are inadequate to protect the population. Only reducing the R(0) of the virus below 1 is an effective strategy for maintaining the death burden of COVID-19 within the normal range of seasonal flu. The model is illustrated with the cases of Italy, France, and Iran and is able to describe the number of deaths as a function of time in all these cases although future projections tend to slightly overestimate the number of deaths when the analysis is made early on. The model can also be used to describe reopenings of the economy after a lockdown. The case mortality rate is still prone to large uncertainty, but modeling combined with an investigation of blood donations in The Netherlands imposes a lower limit of 1%. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11071-020-05861-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7416305
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Netherlands
record_format MEDLINE/PubMed
spelling pubmed-74163052020-08-10 The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses De Visscher, Alex Nonlinear Dyn Original Paper An epidemiological model for COVID-19 was developed and implemented in MATLAB/GNU Octave for use by public health practitioners, policy makers, and the general public. The model distinguishes four stages in the disease: infected, sick, seriously sick, and better. The model was preliminarily parameterized based on observations of the spread of the disease. The model assumes a case mortality rate of 1.5%. Preliminary simulations with the model indicate that concepts such as “herd immunity” and containment (“flattening the curve”) are highly misleading in the context of this virus. Public policies based on these concepts are inadequate to protect the population. Only reducing the R(0) of the virus below 1 is an effective strategy for maintaining the death burden of COVID-19 within the normal range of seasonal flu. The model is illustrated with the cases of Italy, France, and Iran and is able to describe the number of deaths as a function of time in all these cases although future projections tend to slightly overestimate the number of deaths when the analysis is made early on. The model can also be used to describe reopenings of the economy after a lockdown. The case mortality rate is still prone to large uncertainty, but modeling combined with an investigation of blood donations in The Netherlands imposes a lower limit of 1%. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s11071-020-05861-7) contains supplementary material, which is available to authorized users. Springer Netherlands 2020-08-10 2020 /pmc/articles/PMC7416305/ /pubmed/32836820 http://dx.doi.org/10.1007/s11071-020-05861-7 Text en © Springer Nature B.V. 2020 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Paper
De Visscher, Alex
The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
title The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
title_full The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
title_fullStr The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
title_full_unstemmed The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
title_short The COVID-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
title_sort covid-19 pandemic: model-based evaluation of non-pharmaceutical interventions and prognoses
topic Original Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416305/
https://www.ncbi.nlm.nih.gov/pubmed/32836820
http://dx.doi.org/10.1007/s11071-020-05861-7
work_keys_str_mv AT devisscheralex thecovid19pandemicmodelbasedevaluationofnonpharmaceuticalinterventionsandprognoses
AT devisscheralex covid19pandemicmodelbasedevaluationofnonpharmaceuticalinterventionsandprognoses